Joshua Chen

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis
    Y H Joshua Chen
    Merck Research Laboratories, Blue Bell, PA 19422, USA
    Control Clin Trials 24:16-27. 2003
  2. doi request reprint An adaptive strategy for assessing regional consistency in multiregional clinical trials
    Joshua Chen
    Merck Research Laboratories, Rahway, NJ 07026, USA
    Clin Trials 9:330-9. 2012
  3. doi request reprint Testing superiority at interim analyses in a non-inferiority trial
    Y H Joshua Chen
    Merck Research Laboratories, Rahway, NJ, PA, USA
    Stat Med 31:1531-42. 2012
  4. doi request reprint Assessing consistent treatment effect in a multi-regional clinical trial: a systematic review
    Joshua Chen
    Merck Research Labs, UG1CD 44, North Wales, PA, USA
    Pharm Stat 9:242-53. 2010
  5. doi request reprint Some drop-the-loser designs for monitoring multiple doses
    Y H Joshua Chen
    Merck Research Laboratories, North Wales, PA 19454, USA
    Stat Med 29:1793-807. 2010
  6. doi request reprint On methods to utilize HIV-RNA data measured by two different PCR assays
    Y H Joshua Chen
    Clinical Biostatistics, Merck Research Laboratories, North Wales, Pennsylvania 19454, USA
    J Biopharm Stat 18:724-36. 2008
  7. ncbi request reprint Testing for crossover of two hazard functions using Gail and Simon's method
    Y H Joshua Chen
    Clinical Biostatistics, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Biopharm Stat 16:313-26. 2006
  8. ncbi request reprint Treatment comparisons for a partially categorical outcome applied to a biomarker with assay limit
    Y H Joshua Chen
    Merck Research Laboratories, Blue Bell, PA 19422, USA
    Stat Med 24:211-28. 2005
  9. ncbi request reprint Incorporating durability information in the comparison of proportions of patients with HIV suppression
    Y H Joshua Chen
    Merck Research Laboratories, Blue Bell, Pennsylvania 19422, USA
    J Biopharm Stat 14:741-55. 2004
  10. ncbi request reprint Increasing the sample size when the unblinded interim result is promising
    Y H Joshua Chen
    Merck Research Laboratories, Blue Bell, PA 19422, USA
    Stat Med 23:1023-38. 2004

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis
    Y H Joshua Chen
    Merck Research Laboratories, Blue Bell, PA 19422, USA
    Control Clin Trials 24:16-27. 2003
    ..A simulation study shows that the two switching-endpoint procedures allow a trial to be stopped early due to a clinically relevant benefit in the mortality while preserving the overall alpha level...
  2. doi request reprint An adaptive strategy for assessing regional consistency in multiregional clinical trials
    Joshua Chen
    Merck Research Laboratories, Rahway, NJ 07026, USA
    Clin Trials 9:330-9. 2012
    ..Unexpected regional finding may arise and increase the risk of ambiguous or controversial results at the end of the study...
  3. doi request reprint Testing superiority at interim analyses in a non-inferiority trial
    Y H Joshua Chen
    Merck Research Laboratories, Rahway, NJ, PA, USA
    Stat Med 31:1531-42. 2012
    ..Numerical evaluation further supports the conclusion for other alpha-spending functions with a substantial amount of alpha being spent on the interim superiority tests. We use a clinical trial example to illustrate the proposed design...
  4. doi request reprint Assessing consistent treatment effect in a multi-regional clinical trial: a systematic review
    Joshua Chen
    Merck Research Labs, UG1CD 44, North Wales, PA, USA
    Pharm Stat 9:242-53. 2010
    ..A case study is used to illustrate these methods. We also provide recommendations on how to choose appropriate methods and incorporate them in the study design...
  5. doi request reprint Some drop-the-loser designs for monitoring multiple doses
    Y H Joshua Chen
    Merck Research Laboratories, North Wales, PA 19454, USA
    Stat Med 29:1793-807. 2010
    ..The MMA method tends to protect the false positive rate and is more powerful than the Bonferroni-based MMB method. The MMA method offers a practical and flexible solution when there are several doses and multiple interim looks...
  6. doi request reprint On methods to utilize HIV-RNA data measured by two different PCR assays
    Y H Joshua Chen
    Clinical Biostatistics, Merck Research Laboratories, North Wales, Pennsylvania 19454, USA
    J Biopharm Stat 18:724-36. 2008
    ..A simulation study is used to compare these approaches. An example from a clinical trial in HIV-infected patients is used to illustrate the proposed approach...
  7. ncbi request reprint Testing for crossover of two hazard functions using Gail and Simon's method
    Y H Joshua Chen
    Clinical Biostatistics, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Biopharm Stat 16:313-26. 2006
    ..For our purpose, we consider the likelihood ratio test proposed by Gail and Simon. Two examples are used to illustrate this approach. The proposed test procedures are also studied through simulations...
  8. ncbi request reprint Treatment comparisons for a partially categorical outcome applied to a biomarker with assay limit
    Y H Joshua Chen
    Merck Research Laboratories, Blue Bell, PA 19422, USA
    Stat Med 24:211-28. 2005
    ..An example is used to illustrate this approach and a simulation study is used to compare this approach with other methods...
  9. ncbi request reprint Incorporating durability information in the comparison of proportions of patients with HIV suppression
    Y H Joshua Chen
    Merck Research Laboratories, Blue Bell, Pennsylvania 19422, USA
    J Biopharm Stat 14:741-55. 2004
    ..Simulation studies show that this method is more powerful than comparing the success rates alone when the experimental treatment is also more durable in maintaining long term success...
  10. ncbi request reprint Increasing the sample size when the unblinded interim result is promising
    Y H Joshua Chen
    Merck Research Laboratories, Blue Bell, PA 19422, USA
    Stat Med 23:1023-38. 2004
    ..If there are two or more interim analyses in a group sequential trial, our simulation study shows that the type I error rate is also well controlled...
  11. doi request reprint Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium
    Bach Yen T Nguyen
    ISENTRESS Discovery and Development Team, Merck Research Laboratories, North Wales, Pennsylvania 19454 1099, USA
    Ann N Y Acad Sci 1222:83-9. 2011
    ..Raltegravir represents an important addition to the current armamentarium for the treatment of HIV infection...
  12. ncbi request reprint Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy
    Alfred J Saah
    Merck Research Laboratories, West Point, PA 19486, USA
    J Infect Dis 187:1157-62. 2003
    ..Suppression to <400 viral RNA copies/mL was achieved at week 48 in 56% of patients with the D30N virus versus 18% of patients with the L90M virus...